Bristol Myers inks another Revlimid patent settlement—this time with Sun Pharma—as copycats near

As Bristol Myers Squibb looks to guard Celgene’s top-selling cancer drug Revlimid from copycat competition, the company has inked a series of deals to welcome generic challengers in waves. India’s Sun Pharmaceutical is the latest to get in on the action.